Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the cancellation of the Company’s presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place on March 3, 2020 at 9:20 a.m. Eastern Time. Management will no longer be attending the conference as a precautionary measure related to travel amidst the evolving coronavirus situation.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-ejfv) use the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Investors: Peggy Pinkston (425) 527-4160 ppinkston@seagen.com

Media: Monique Greer (425) 527-4641 mgreer@seagen.com

Seattle Genetics (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Seattle Genetics Charts.
Seattle Genetics (NASDAQ:SGEN)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Seattle Genetics Charts.